We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Cognate

News List

Cobra Biologics, CombiGene Ready to Start GMP Production of Epilepsy Drug Candidate contractpharma
June 28, 2021
Complete production and quality assurance of the plasmids to be used in the GMP production of CG01.
Charles River Acquires CDMO Cognate BioServices contractpharma
February 18, 2021
Charles River Laboratories has signed an agreement to acquire Cognate BioServices, a cell and gene therapy contract development and manufacturing organization (CDMO), for approximately $875 million.
Cognate BioServices, Nucleus Biologics Form Cell & Gene Therapy Partnership contractpharma
February 01, 2021
Cognate BioServices, a global contract development and manufacturing organization (CDMO) in the cell and gene therapy industry, and Nucleus Biologics, have formed a partnership for custom and commercial medias and delivery systems for cell and gene ...
Cognate BioServices Announces Major Expansion contractpharma
January 19, 2021
Cognate BioServices Inc. has announced plans to expand cell and gene therapy manufacturing capacity, laboratory space, warehousing capabilities, and increase office support at its facilities in the United States and Europe.
Caladrius, Cognate Ink Clinical Manufacturing Agreement contractpharma
August 13, 2019
For phase 3 trial of CLBS14 in no-option refractory disabling angina.